M. Craig Shepherd is a Senior Managing Director focused on life sciences investing across the firm's businesses.
Before joining Blackstone, Mr. Shepherd worked for the prior seven years as a Managing Director with DRI Capital, a life sciences private equity firm dedicated to the acquisition of pharmaceutical royalties through its managed funds Drug Royalty I, II and III. From 2010-2017, Mr. Shepherd was a member of the DRI Investment Committee and leadership team, and he also served on the board of DRI’s third fund, Drug Royalty III GP. Prior to DRI, he worked at Amgen for approximately eight years in various roles of progressive responsibility, based at both Amgen’s global headquarters in California and its international headquarters in Switzerland.
Mr. Shepherd holds an MBA from Harvard Business School, a law degree from McGill University and a BA from the University of Western Ontario. Mr. Shepherd serves as a Trustee of the American Kidney Fund, and as a corporate director of Medcan Health Management.